What we do Tyche Industries Ltd is a leading Indian manufacturer specializing in Glucosamine Hydrochloride and pharmaceutical bulk drug intermediates primarily for export to the USA and Europe. |
Founded in 1,998 |
Market share Among the largest manufacturers in India of glucosamine hydrochloride and salts with significant export market presence in US and Europe. |
Problem solved Provides high-quality pharmaceutical intermediates and APIs meeting regulatory standards to address global demand for advanced drug components. |
Top clients or who we serve Serves global pharmaceutical companies and nutraceutical manufacturers, primarily B2B clients in regulated markets of USA and Europe. |
Key management G. Ganesh Kumar (Chairman & Managing Director) leads with significant industry experience. |
Our journey and innovations Founded in 1998, expanded into fine chemicals in 2004, developed FDA-approved facilities and advanced R&D centers in USA and India. |
Where we operate Predominantly exports to USA and Europe with operations and manufacturing in India and development centers in USA and Hyderabad. |
Top products or what we offer Manufacture of Glucosamine Hydrochloride, APIs, intermediates, and nutraceutical ingredients with FDA-approved plants. |
Top brands - |
Raw materials needed Chemical raw materials for glucosamine derivatives and bulk drug intermediates. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is primarily recurring through sustained global pharma supply contracts. |
Our industry position Key player with strong export focus, recognized compliance, and competitive manufacturing in pharmaceutical intermediates. |
Financial highlights FY 2024-25 revenue of ₹65.47 crore with net profit of ₹12.41 crore, sustaining profitability despite slight revenue dip. |
Geographical revenue split Revenue split around 33% domestic and 47% export operations with significant international sales. |
Order book - |
Whats driving growth Exports growth driven by regulatory approvals, pharma sector demand, and strategic global partnerships. |
Our future plans Plans to increase ANDA filings, expand manufacturing capabilities and enhance R&D for advanced pharmaceutical products. |
Our green promise - |
Our people and values Focus on employee development, inclusion, compliance with workplace safety and maternity benefits. |
Key challenges ahead Regulatory compliance, currency fluctuations, and competition in global pharma intermediates market. |
Interesting facts Awarded Asia's 200 Best under A Billion by Forbes in 2020. |
Risks and strategy Mitigates manufacturing, regulatory, and market risks with robust internal controls, compliance frameworks, and diversification. |
